livestreamedcollapse

joined 1 year ago
[–] livestreamedcollapse@lemmy.ml 3 points 20 hours ago* (last edited 20 hours ago) (1 children)

https://en.cancer.org.il/news_e/new.aspx?NewId=227

Global achievement recorded in Israel - melanoma incidence rates have declined by 30% among Jewish women and stability has been observed among Jewish men

After a government education program to promote sunscreen use lmao.

Among the Arab population in Israel, melanoma is a rare disease and the morbidity rates amount to no more than a handful of cases.

How do you get the 30% reduction if you're not as "white skinned" as we've been led to believe? Sounds like you're just thin skinned because you know you're repeating history.

[–] livestreamedcollapse@lemmy.ml 2 points 20 hours ago* (last edited 20 hours ago)

lysdexamphetamine (Vyvanse) is an interesting prodrug version of Adderall that often gets joked about by Felix & a low dosage might address both the short half life of Ritalin while not keeping you too wired to sleep.

The strategy for Adderall XR is having slow release encapsulation, plus different amphetamine salts which take varied amounts of time to become active.

Vyvanse instead attaches a lysine amino acid to the amphetamine molecule, rendering it inert until an enzyme in your bloodstream cleaves off the lysine, yielding the active form.

This prodrug strategy eliminates variables that might affect the release rate of the active drug from an XR capsule before it hits your bloodstream, meaning you get a "spikier" release profile instead of a low & slow consistent dose curve. Variables like a lower stomach pH, which promotes quicker degradation of encapsulation material or how fast the various salts dissociate from the active amphetamine molecule. With the lysine prodrug it doesn't matter how much of the prodrug enters your bloodstream, it's release rate is tied to how quickly that enzyme can cleave the lysine off the amphetamine.

[–] livestreamedcollapse@lemmy.ml 3 points 1 day ago* (last edited 1 day ago) (1 children)

They're a feddie plot to divide us spacenoids & steal money for dues that we could otherwise have spent on a PlayStation 17! I read it in the latest Q drop posted by those cyber newtypes at the 4Chanagan Institute

[–] livestreamedcollapse@lemmy.ml 3 points 1 day ago (3 children)

Inspiring words, oh great Degwin! With undying revolutionary zeal for the spacenoid cause, I shall triple my efforts as an optics tech at the colony laser!

[–] livestreamedcollapse@lemmy.ml 4 points 1 day ago (5 children)

Idk if you're taking requests but if so can you have Degwin speak about his beautiful daughter, Kycillia, & future son in law Jared M'quve?

[–] livestreamedcollapse@lemmy.ml 5 points 2 days ago (1 children)

With the inherent biases present in any LLM training model, the issue of hallucinations that you've brought up, alongside the cost of running an LLM at scale being prohibitive to anyone besides private-state partnerships, do you think that will allay conspiracists' valid concerns about the centralization of information access, a la the reduction in quality google search results over the past decade and a half?

[–] livestreamedcollapse@lemmy.ml 3 points 2 days ago* (last edited 2 days ago)

GOOD advice. I called a uh, "pharmacological audible" switching from Sertraline (Zoloft) to Bupropion XR by asking an RN to prescribe the latter during my 1st quarter of pharm sci/med chem PhD after the Sertraline showed signs it definitely wasn't working. Felt much better but they still mastered me out a couple years later. I went off it during COVID just to see how I'd fare without & was mostly fine at my 1st job out of school working at a drug delivery startup, but have been considering going back on it; like MeowZedong said, this is a small field & I feel like I'm having a hard time staying motivated to apply for job listings that may get as many as ~500 applicants—all more credentialed than I—ever since that 4 person startup I was working for went under last year.

One thing to note with Bupropion is skipping 4 days can cause mild amphetamine psychosis, so don't learn that the hard way when transferring the prescription to a pharmacy that's closed on weekends. 3-chloro- N-tert butylcathinone, where cathinone is the active ingredient of khat, might've been a giveaway with a pharmacophore like that!

Painful to read. You missed your chance to make a hot tub with your beam saber & invite them to skinny dip right then and there

[–] livestreamedcollapse@lemmy.ml 2 points 1 week ago* (last edited 1 week ago)

Dr. Spoon's more credentialed than my washed out academic career; my hating has been defeated by meritocracy!

The ghosties scared me as an 9 year old.

[–] livestreamedcollapse@lemmy.ml 2 points 1 week ago* (last edited 1 week ago) (2 children)

Not to mention meeting standards of purity and formulating your medication so it's shelf stable and the active pharm ingredient can be distributed within the body effectively once the medicine is administered.

I've had similar thoughts as these jokers but with using bioreactors. Each time I conclude that the solution is a centralized manufacturing facility owned by workers to effectively produce at scale (and ensure you don't poison people).

Sure, you're not gonna build that misoprostol plant in Texas, but there's other options to obtain properly-manufactured medication before you drink a mystery brew cooked up by an anarchist squatter named Spoon.

[–] livestreamedcollapse@lemmy.ml 3 points 1 week ago* (last edited 1 week ago) (4 children)

Absolutely, and I don't see biohackers offering up cheap NMR or MS/MS detectors to solve the common issue of inadvertently making side products like MPTP when attempting to cook up MPPP or whatever, consequently injecting Parkinson's into yourself. So you're still bound by the enormous costs of getting an analytical lab stood up, despite using "AI" assisted synthetic software to substitute for real verification of each purified intermediate product. Also my other chem friend & I think that Vinni guy is an annoying ted-talk dude fwiw.

view more: next ›